MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...

Cognitive biases impact how both patients and non-patients think about MS, says columnist Ben Hofmeister, who calls education the best remedy.

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

Frustrated by past New Year's resolutions, columnist Desiree Lama is setting intentions to help redefine what progress with ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

Mothers with MS face longer diagnostic delays than women without children, especially those who are employed or single.

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...